Access Program for Talquetamab in Treating Difficult or Returning Multiple Myeloma
Sponsor: Janssen Research & Development, LLC
ClinicalTrials ID:NCT05757973
This program provides access to the drug talquetamab for patients with multiple myeloma that has returned or is hard to treat, and who have no other treatment options available and cannot join a clinical trial.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The goal of this program is to offer the drug talquetamab to patients with multiple myeloma, a cancer of the plasma cells, who have tried all available treatments without success and are not eligible for clinical trials. Talquetamab is given as a single drug treatment to help manage the disease.
Description
Talquetamab is a special type of antibody designed to help the immune system target and destroy cancer cells in multiple myeloma. It works by directing immune cells to attack cancer cells that have specific markers. The drug is given as an injection under the skin. During the program, doctors will closely monitor patients for any side effects or reactions to the drug to ensure it is safe and effective.
Eligibility Criteria
Inclusion Criteria
- Diagnosed with multiple myeloma that has returned or is difficult to treat.
- Have tried all approved treatments available and are not eligible for any clinical trials.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.